Cargando…

Tailoring Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A CYP2D6 Multiple-Genotype-Based Modeling Analysis and Validation

PURPOSE: Previous studies have suggested that postmenopausal women with breast cancer who present with wild-type CYP2D6 may actually have similar or superior recurrence-free survival outcomes when given tamoxifen in place of aromatase inhibitors (AIs). The present study established a CYP2D6 multiple...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Ke-Da, Huang, A-Ji, Shao, Zhi-Ming
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004945/ https://www.ncbi.nlm.nih.gov/pubmed/21187922 http://dx.doi.org/10.1371/journal.pone.0015649

Ejemplares similares

Association of adjuvant aromatase inhibitor with cataract risk in postmenopausal women with breast cancer
por: Chen, Han, et al.
Publicado: (2020)

An unmet need: tailoring extended adjuvant endocrine therapy
por: Bianchini, G, et al.
Publicado: (2013)

Establishment of CYP2D6 Reference Samples by Multiple Validated Genotyping Platforms
por: Fang, Hua, et al.
Publicado: (2014)

Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer
por: Güth, U, et al.
Publicado: (2008)

Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update
por: Mokbel, Ramia, et al.
Publicado: (2006)

CYP2D6 genotype affects outcome in postmenopausal breast cancer patients treated with tamoxifen monotherapy
por: Thompson, AM, et al.
Publicado: (2010)

Tailored Thienopyridine Therapy: No Urgency for CYP2C19 Genotyping
por: Fontana, Pierre, et al.
Publicado: (2013)

CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations
por: Province, M A, et al.
Publicado: (2014)

National Prociency Testing Result of CYP2D6*10 Genotyping for Adjuvant Tamoxifen Therapy in China
por: Lin, Guigao, et al.
Publicado: (2016)

De‐escalation of five‐year adjuvant endocrine therapy in patients with estrogen receptor‐low positive (immunohistochemistry staining 1%‐10%) breast cancer: Propensity‐matched analysis from a prospectively maintained cohort
por: Cai, Yu‐Wen, et al.
Publicado: (2022)

Correction: National Prociency Testing Result of CYP2D6*10 Genotyping for Adjuvant Tamoxifen Therapy in China
Publicado: (2016)

Methodology for clinical genotyping of CYP2D6 and CYP2C19
por: Carvalho Henriques, Beatriz, et al.
Publicado: (2021)

CYP2D6 genotype and tamoxifen response
por: Rae, James M, et al.
Publicado: (2005)

The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial
por: Gnant, M, et al.
Publicado: (2013)

Efficacy and Safety of Initial 5 Years of Adjuvant Endocrine Therapy in Postmenopausal Hormone Receptor-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis
por: Liao, Hao, et al.
Publicado: (2022)

Correction: Methodology for clinical genotyping of CYP2D6 and CYP2C19
por: Henriques, Beatriz Carvalho, et al.
Publicado: (2022)

Combined effect of CYP1B1, COMT, GSTP1, and MnSOD genotypes and risk of postmenopausal breast cancer
por: Cerne, Jasmina-Ziva, et al.
Publicado: (2011)

Adjuvant endocrine monotherapy for postmenopausal early breast cancer patients with hormone-receptor positive: a systemic review and network meta-analysis
por: Yu, Zhu, et al.
Publicado: (2017)

CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer
por: Love, Richard R, et al.
Publicado: (2013)

Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy
por: Mulder, Tessa A. M., et al.
Publicado: (2021)

The Impact of CYP2D6 Genotyping on Tamoxifen Treatment
por: Ferraldeschi, Roberta, et al.
Publicado: (2010)

Status of adjuvant endocrine therapy for breast cancer
por: Schiavon, Gaia, et al.
Publicado: (2014)

Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT
por: Pagani, Olivia, et al.
Publicado: (2020)

Genotype-phenotype correlation in multiple endocrine neoplasia type 2
por: Raue, Friedhelm, et al.
Publicado: (2012)

Predictive role of HER2-status on the effectiveness of endocrine adjuvant treatment in postmenopausal breast cancer patients: a population-based cohort study
por: Schiza, Aglaia, et al.
Publicado: (2020)

Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
por: Butani, Dimple, et al.
Publicado: (2021)

Tailored duration of adjuvant trastuzumab for human epidermal growth factor receptor 2-positive breast cancer
por: Yu, Ke-Da, et al.
Publicado: (2020)

Exemestane in the Adjuvant Treatment of Breast Cancer in Postmenopausal Women
por: Kittaneh, Muaiad, et al.
Publicado: (2011)

CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment
por: Beelen, K., et al.
Publicado: (2013)

Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6‐Mediated Metabolic Activity
por: Dalton, Rachel, et al.
Publicado: (2019)

High dose ketoconazole: endocrine and therapeutic effects in postmenopausal breast cancer.
por: Harris, A. L., et al.
Publicado: (1988)

Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.
por: Dowsett, M., et al.
Publicado: (1984)

Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors
por: Matthews, Anthony A, et al.
Publicado: (2021)

Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of CYP2D6, CYP2B6, and CYP3A4 genotype
por: Haage, Pernilla, et al.
Publicado: (2018)

CYP2B6 Genotype‐Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers
por: Metzger, Ingrid F., et al.
Publicado: (2019)

Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes
por: Kim, Se-Hyung, et al.
Publicado: (2018)

Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients
por: Rosso, Roberta, et al.
Publicado: (2023)

Improved adjuvant endocrine therapy for premenopausal women with endocrine responsive disease
por: Goldhirsch, Aron, et al.
Publicado: (2015)

CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients
por: Sirachainan, Ekaphop, et al.
Publicado: (2012)

Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer
por: Yu, Ke-Da, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_enuepspvtmgebucr4emuc5pv5s